Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs American Express Co (AXP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs American Express Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.7 (market cap $39.89B), while American Express Co trades at $355.86 (market cap $239.21B). The key difference: American Express Co is far larger — about 6× Alnylam Pharmaceuticals, Inc.'s market cap, and American Express Co pays a 1.08% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AXP | |
|---|---|---|
Market Cap | $39.89B | $239.21B |
Sector | Health | Financials |
52-Week High | $491.22 | $384.82 |
52-Week Low | $278.09 | $292.27 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
American Express (AXP) trades at $350.58, up 1.11% today, with a bullish technical signal and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and the company is expanding its premium cardholder perks and AI initiatives, including a new NFL partnership and headquarters development at 2 World Trade Center.
The outlook is positive with a consensus price target of $375.27, implying 7% upside. Risks include economic sensitivity and competitive pressures, but robust consumer spending and innovation in digital payments support growth. Analyst sentiment is mixed with 38.6% buy ratings, highlighting potential for steady gains amid macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
